Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Imatinib

Adjuvant Study 1 (ACOSOG Z9001)

Novartis · Phase 3 · Completed · Enrollment 732

NCT00041197

ArmReported safety
Imatinib 400 mg for 12 monthsn/r

A count stays a count. This page does not turn a count into a percent.